Authors
Latest:
Dr Massarelli on the Current SCLC Treatment ArmamentariumErminia Massarelli, MD, PhD, MS, discusses clinical gaps in lung cancer care that were highlighted at the 2023 Bridging the Gaps in Lung Cancer meeting, emphasizing the importance of molecular testing in patients with small cell lung cancer and collaborations between health care networks in this treatment arena.
Latest:
Dr Chudgar on Defining Resectability in NSCLCNeel P. Chudgar, MD, discusses his presentation on resectability in non–small cell lung cancer at the 21st Annual Winter Lung Cancer Conference®.
Latest:
Dr Jha on Community Accrual to the ECLIPSE Trial in Prostate CancerGautam Jha, MD, discusses collaborative efforts between community and academic oncologists to accrue patients to the ECLIPSE trial.
Latest:
Dr. Mark on Questions Regarding Sequencing in Multiple MyelomaTomer Mark, MD, discusses making sequencing decisions amid the array of available treatment options in multiple myeloma.
Latest:
Drs Gerber and Nwachukwu on the Importance of Streamlining Clinical Research in Cancer CareDavid Gerber, MD, and Chika Nwachukwu, MD, PhD, discuss their role within the Stand Up To Cancer® 4-team initiative, focusing on diversity in early-phase clinical trials.
Latest:
Dr. Venkat on Unmet Needs in Ovarian CancerPuja S. Venkat, MD, discusses unmet needs in ovarian cancer.
Latest:
BRIGHTSTAR: Local Consolidative Therapy with Brigatinib in Tyrosine Kinase Inhibitor-Naïve ALK-Rearranged Metastatic NSCLCExpert oncologist Yasir Elamin, MD, shares data from the BRIGHTSTAR trial and considers how it may inform real-world use of brigatinib in patient with ALK-rearranged metastatic non–small cell lung cancer.
Latest:
Dr. Siddiqui on Defining Characteristics of Nonmetastatic CRPCBilal A. Siddiqui, MD, discusses the nuances of defining the characteristics of nonmetastatic castration-resistant prostate cancer.
Latest:
Dr. Raj on Injection Site Pain With Octreotide Long-Acting Release Vs Lanreotide in NETsNitya Raj, MD, discusses the results of a phase 4 trial comparing injection site pain with octreotide long-acting release vs lanreotide in well-differentiated neuroendocrine tumors.
Latest:
Exploring Emerging Data in DLBCLA panel of experts in lymphoma reflect on major data that came out of the ASCO 2021 Virtual Meeting.
Latest:
Dr. Roque on the Importance of Biomarker Testing in Advanced Endometrial CancerDario R. Roque, MD, discusses how biomarker testing can lead to more accurate and effective treatment selection in advanced endometrial cancer.
Latest:
Dr. Weiss on Selecting Optimal Radiation Therapy for Brain MetastasesStephanie E. Weiss, MD, FASTRO, discusses selecting optimal radiation therapy for patients with brain metastases.
Latest:
Dr Huang on the Use of Neoadjuvant PARP Inhibitors in Advanced Ovarian CancerMarilyn Huang, MD, discusses the need for non-chemotherapy options in advanced ovarian cancer, as well as data on the use of neoadjuvant PARP inhibitors for this population in the phase 1 NOW study.
Latest:
Dr Imanirad on Toxicity Management for Encorafenib Plus Cetuximab in BRAF-Mutant mCRCIman Imanirad, MD, medical oncologist, gastrointestinal oncology, Moffitt Cancer Center, discusses the management of toxicities associated with standard-of-care encorafenib plus cetuximab for patients with previously treated microsatellite stable BRAF V600E metastatic colorectal cancer.
Latest:
Dr. Mahal on the Emerging Role of Epigenomics in Prostate CancerBrandon Mahal, MD, discusses the emerging role of epigenomics in prostate cancer.
Latest:
The COVID-19 Pandemic Will Have Long-Term Impact on Oncology PracticesThe COVID-19 pandemic created new patient care challenges in oncology, such as how to reduce risks of virus exposure for patients who may be immunocompromised and switching from in-person visits to telemedicine.
Latest:
Dr Advani on the Evaluation of Ribociclib/Endocrine Therapy in HR+/HER2– Breast CancerPooja Advani, MBBS, MD, discusses the use of ribociclib plus endocrine therapy for patients with hormone receptor–positive, HER2– breast cancer.
Latest:
Cleveland Clinic and IBM Researchers Publish Findings on Artificial Intelligence and ImmunityThe study, published in Briefings in Bioinformatics, highlights how artificial intelligence can be designed to develop better immunotherapy treatments.
Latest:
Dr Girda on the Use of Pembrolizumab Plus Chemotherapy in Endometrial CancerEugenia Girda, MD, FACOG, discusses the use of pembrolizumab plus chemotherapy for patients with endometrial cancer as seen in the phase 3 NRG-GY018 trial.
Latest:
HCC International Clinical TrialsClosing the discussion on HCC systemic therapies, Drs Abou-Alfa, Lewandowski and Singal review international clinical trials and access to treatments.
Latest:
Dr. Neumann on Tapering Steroids in cGVHDJoyce L. Neumann, PhD, APRN, AOCN, BMTCN, FAAN, discusses tapering steroids for patients with chronic graft-vs-host disease.
Latest:
Dr Zhou on Ongoing Investigations into the Treatment of Patients With Myelofibrosis and AnemiaAmy W. Zhou, MD, discusses ongoing and planned trials that may enhance therapeutic options for patients with myelofibrosis and anemia that are currently taking place at the Washington University School of Medicine in St. Louis.
Latest:
Question and Answer SessionDr Gary Ulaner and Dr Jeremy Force answer questions submitted by attendees of the live webinar discussing the role of various strategies to detect estrogen receptor (ER)-positive breast cancer, with particular focus on the role of 18-F FES-PET imaging in diagnosis and treatment of ER-positive breast cancer.
Latest:
Dr Mastroyannis on the Continued Investigation of Targeted Therapies in Ovarian CancerS. Alex Mastroyannis, MD, MSCE, discusses the management of gynecologic cancers, such as metastatic or recurrent ovarian and endometrial cancers.
Latest:
Women in Oncology: Prioritization and Passionate LegaciesSelina M. Luger, MD, FRCPC, Gail J. Roboz, MD, and Wendy Stock, MD, discuss how being female affected their careers and share the scientific achievements they most want to be remembered for in the leukemia field.
Latest:
Dr. Finn on the Utility of Belantamab Mafodotin in Late Relapsed Multiple MyelomaLaura Finn, MD, discusses the utility of belantamab mafodotin-blmf in late relapsed multiple myeloma.
Latest:
First-Line Therapy in Advanced Clear Cell RCC: Novel Doublet RegimensAn expert panel reviews novel first-line doublet therapies being studied in patients with advanced clear cell renal cell carcinoma.
Latest:
Dr. Ryan on the Efficacy of Ibrutinib Plus Obinutuzumab in Relapsed/Refractory CLLChristine Ryan, MD, discusses the significance of data for ibrutinib plus obinutuzumab in relapsed/refractory chronic lymphocytic leukemia.
